Typhoid conjugate vaccine perceptions and coverage among children and adults: Findings from a post-campaign coverage survey - Harare, Zimbabwe, 2019.

Disease outbreaks Typhoid fever Vaccination coverage Vaccines, conjugate Zimbabwe

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
10 Jul 2024
Historique:
received: 08 03 2024
revised: 28 05 2024
accepted: 22 06 2024
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 11 7 2024
Statut: aheadofprint

Résumé

In 2019, following a large outbreak of typhoid fever, the Zimbabwe Ministry of Health and Child Care conducted a typhoid conjugate vaccine (TCV) vaccination campaign in nine high-risk suburbs of Harare. We aimed to evaluate TCV vaccination coverage, vaccine perceptions, and adverse events reported after vaccination. We conducted a two-stage cluster survey to estimate vaccination coverage in the campaign target areas among children aged 6 months-15 years and to classify coverage as either adequate (≥75 % coverage) or inadequate (<75 % coverage) among adults aged 16-45 years in one suburb. Questionnaires assessed socio-demographic factors, TCV vaccination history, reasons for receiving or not receiving TCV, adverse events following immunization, and knowledge and attitudes regarding typhoid and TCV. A total of 1,917 children from 951 households and 298 adults from 135 households enrolled in the survey. Weighted TCV coverage among all children aged 6 months-15 years was 85.3 % (95 % CI: 82.1 %-88.0 %); coverage was 74.8 % (95 % CI: 69.4 %-79.5 %) among children aged 6 months-4 years and 89.3 % (95 % CI: 86.2 %-91.7 %) among children aged 5-15 years. Among adults, TCV coverage was classified as inadequate with a 95 % confidence interval of 55.0 %-73.1 %. Among vaccinated persons, the most reported reason for receiving TCV (96 % across all age groups) was protection from typhoid fever; the most common reasons for non-vaccination were not being in Harare during the vaccination campaign and not being aware of the campaign. Adverse events were infrequently reported in all age groups (10 %) and no serious events were reported. The 2019 TCV campaign achieved high coverage among school-aged children (5-15 years). Strategies to increase vaccination coverage should be explored for younger children as part of Zimbabwe's integration of TCV into the routine immunization program, and for adults during future post-outbreak campaigns.

Sections du résumé

BACKGROUND BACKGROUND
In 2019, following a large outbreak of typhoid fever, the Zimbabwe Ministry of Health and Child Care conducted a typhoid conjugate vaccine (TCV) vaccination campaign in nine high-risk suburbs of Harare. We aimed to evaluate TCV vaccination coverage, vaccine perceptions, and adverse events reported after vaccination.
METHODS METHODS
We conducted a two-stage cluster survey to estimate vaccination coverage in the campaign target areas among children aged 6 months-15 years and to classify coverage as either adequate (≥75 % coverage) or inadequate (<75 % coverage) among adults aged 16-45 years in one suburb. Questionnaires assessed socio-demographic factors, TCV vaccination history, reasons for receiving or not receiving TCV, adverse events following immunization, and knowledge and attitudes regarding typhoid and TCV.
RESULTS RESULTS
A total of 1,917 children from 951 households and 298 adults from 135 households enrolled in the survey. Weighted TCV coverage among all children aged 6 months-15 years was 85.3 % (95 % CI: 82.1 %-88.0 %); coverage was 74.8 % (95 % CI: 69.4 %-79.5 %) among children aged 6 months-4 years and 89.3 % (95 % CI: 86.2 %-91.7 %) among children aged 5-15 years. Among adults, TCV coverage was classified as inadequate with a 95 % confidence interval of 55.0 %-73.1 %. Among vaccinated persons, the most reported reason for receiving TCV (96 % across all age groups) was protection from typhoid fever; the most common reasons for non-vaccination were not being in Harare during the vaccination campaign and not being aware of the campaign. Adverse events were infrequently reported in all age groups (10 %) and no serious events were reported.
CONCLUSIONS CONCLUSIONS
The 2019 TCV campaign achieved high coverage among school-aged children (5-15 years). Strategies to increase vaccination coverage should be explored for younger children as part of Zimbabwe's integration of TCV into the routine immunization program, and for adults during future post-outbreak campaigns.

Identifiants

pubmed: 38991917
pii: S0264-410X(24)00727-8
doi: 10.1016/j.vaccine.2024.06.053
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Radhika Gharpure (R)

US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Ashley T Longley (AT)

US Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: uyn8@cdc.gov.

Mayuko Takamiya (M)

PHI/CDC Global Health Fellowship, Harare, Zimbabwe.

Anna Hidle (A)

CDC Foundation, Atlanta, GA, USA.

Manes Munyanyi (M)

Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.

Trymore Chawurura (T)

Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.

Linda Maxwell (L)

Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.

George Mamire (G)

Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.

Grace Chaora (G)

Zimbabwe National Statistics Agency, Harare, Zimbabwe.

Jethro Chakauya (J)

World Health Organization, Regional Office for Africa, Inter-country Support Team, Harare, Zimbabwe.

Maxwell Rupfutse (M)

World Health Organization, Harare, Zimbabwe.

Marc Poncin (M)

World Health Organization, Harare, Zimbabwe.

Alex Gasasira (A)

World Health Organization, Harare, Zimbabwe.

Kashmira Date (K)

US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Portia Manangazira (P)

Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe.

Nandini Sreenivasan (N)

US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Classifications MeSH